Status:

TERMINATED

Screening Protocol

Lead Sponsor:

Topcon Corporation

Conditions:

Glaucoma

Eligibility:

All Genders

22+ years

Brief Summary

The objective of this study is to collect data for the development and validation a screening process using aggregate data. In this study, data collection will encompass both retrospective and prospe...

Eligibility Criteria

Inclusion

  • Subjects 22 years of age or older on the date of data collection (retrospective) or informed consent (prospective).
  • For prospective data collection or missing retrospective data collection, subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent.
  • BCVA 20/40 or better (each eye).
  • Normal eyes to have normal ocular examination in both eyes
  • Normal eyes to have IOP ≤ 21 mmHg in both eyes
  • Pathology eyes to have clinical diagnosis of mild or moderate glaucoma in at least one eye

Exclusion

  • For prospective or missing retrospective data collection, subjects unable to tolerate ophthalmic testing.
  • Concomitant diseases known to affect the visual field: history of leukemia, dementia, Parkinson's disease, Alzheimer's disease, stroke, or autoimmune diseases.
  • History of intraocular surgery (uncomplicated cataract or glaucoma surgeries are accepted)
  • Ocular findings or history of co-morbidities, including, but not limited to: uveitis, non-glaucomatous optic neuropathy, trauma, retinal detachment, vein or artery occlusions, wet age-related macular degeneration, geographic atrophy, proliferative diabetic retinopathy, vitreous hemorrhage, severe cataract, severe non-proliferative diabetic retinopathy. Controlled diabetes and hypertension participants can be included.
  • Unreliable VF testing and/or poor-quality OCT scans.
  • Poor fixation.
  • Pathology eyes with severe glaucoma
  • Pathology eyes with glaucoma suspect diagnosis
  • Pathology eyes with Ocular Hypertensive diagnosis

Key Trial Info

Start Date :

November 7 2023

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 2 2024

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT06135727

Start Date

November 7 2023

End Date

August 2 2024

Last Update

September 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Topcon

La Jolla, California, United States, 92037

Screening Protocol | DecenTrialz